Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders for Revelation Biosciences, Inc. held on June 23, 2025. The meeting addressed corporate governance, equity plans, executive compensation, and strategic capital structure adjustments.
Key Financial Metrics
This filing is a current report regarding corporate actions and does not contain financial statements, revenue, profit, cash flow, or debt metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Voting Results
Stockholders voted on eight proposals. A quorum was established with 796,075 shares present (approximately 39% of outstanding shares). Key outcomes include:
- Approved: Election of Lakhmir Chawla as Class C Director.
- Approved: Amendment to the 2021 Equity Incentive Plan to allow quarterly "evergreen" share adjustments.
- Approved: Advisory vote on executive compensation and a three-year frequency for future votes.
- Approved: Discretionary authority for the Board to execute reverse stock splits (ratio 1-for-2 to 1-for-250) within one year.
- Approved: Issuance of common stock in excess of the 20% Exchange Cap related to Class H Warrants.
- Failed: Proposal to change corporate domicile from Delaware to Nevada. While 89% of voting shares present supported the move, it did not meet the required threshold of affirmative votes from total outstanding shares.
- Approved: Ratification of Baker Tilly US, LLP as the independent auditor.
Guidance, Outlook, and Management Commentary
CEO James Rolke provided a presentation on recent corporate updates and project developments, furnished as Exhibit 99.1. The filing notes that this presentation is not deemed "filed" for liability purposes under Section 18 of the Exchange Act. No specific financial guidance or forward-looking projections were included in the text of this report.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and timing, as the Board retains discretion to set the ratio between 1-for-2 and 1-for-250.
- Review the implications of the failed domicile change on the company's legal and tax structure.
- Examine the terms of the Class H Warrants and the potential dilution from issuances exceeding the 20% Exchange Cap.
- Consult the June 2025 Annual Meeting Corporate Presentation (Exhibit 99.1) for details on project developments mentioned by management.